title: Comparison of gadobenate dimeglumine (Gd-BOPTA) with gadopentetate dimeglumine (Gd-DTPA) for enhanced MR imaging of brain and spine tumours in children.
abstract: BACKGROUND
  Gadobenate dimeglumine (Gd-BOPTA) demonstrates superior enhancement of brain tumours in adult patients than Gd-DTPA.
  
  
  OBJECTIVE
  To determine whether Gd-BOPTA has advantages over Gd-DTPA for enhanced MR imaging of paediatric brain and spine tumours.
  
  
  METHODS
  Sixty-three subjects, aged 6 months to 16 years, who were enrolled in a prospective, fully blinded, randomized parallel-group phase III clinical trial, received 0.1 mmol/kg doses of either Gd-BOPTA (n=29) or Gd-DTPA (n=34). The MR images were acquired before and within 10 min of contrast agent injection. The primary objective was to compare the difference from pre-dose to post-dose lesion visualization between Gd-BOPTA and Gd-DTPA. Lesion visualization was determined as the sum of individual scores for three criteria of lesion morphological characteristics (lesion border delineation, internal morphology, and contrast enhancement), each assessed qualitatively using 4-point scales. Quantitative evaluation compared changes in lesion-to-background (LBR) and contrast-to-noise (CNR) ratios and per cent enhancement. Monitoring for adverse events and evaluation of vital signs and laboratory values was performed.
  
  
  RESULTS
  Pre-dose to post-dose changes in lesion visualization were significantly better for Gd-BOPTA for both lesion level (2.68+/-2.17 vs. 1.05+/-1.90, P=0.0106) and patient level (2.55+/-2.18 vs. 1.14+/-1.68, P=0.0079) comparisons. The mean pre-dose to post-dose change in CNR was greater for Gd-BOPTA (9.13+/-15.36) than Gd-DTPA (2.18+/-9.90), but the difference was only marginally significant (P=0.0779; 95% CI: -0.553, 14.454) because of wide variations of signal intensity between lesions. Similar findings were obtained for LBR and per cent enhancement. No differences between the agents were noted in terms of safety parameters.
  
  
  CONCLUSIONS
  At an equivalent dose Gd-BOPTA is significantly better than Gd-DTPA for visualization of enhancing CNS tumours in paediatric patients.
authors.affiliation: Department of Clinical Sciences and Bioimaging, Section of Radiology, University, G. d'Annunzio, Chieti, Italy.
authors.forename: Cesare
authors.initials: C
authors.lastname: Colosimo
authors.forename: Philippe
authors.initials: P
authors.lastname: Demaerel
authors.forename: Paolo
authors.initials: P
authors.lastname: Tortori-Donati
authors.forename: Catherine
authors.initials: C
authors.lastname: Christophe
authors.forename: Mark
authors.initials: M
authors.lastname: Van Buchem
authors.forename: Barry
authors.initials: B
authors.lastname: Högström
authors.forename: Gianpaolo
authors.initials: G
authors.lastname: Pirovano
authors.forename: Ningyan
authors.initials: N
authors.lastname: Shen
authors.forename: Miles A
authors.initials: MA
authors.lastname: Kirchin
authors.forename: Alberto
authors.initials: A
authors.lastname: Spinazzi
mesh_terms: D000293:Adolescent; D001932:Brain Neoplasms / Q000175:diagnosis*; D002648:Child; D002675:Child, Preschool; D003287:Contrast Media / Q000008:administration & dosage; D004311:Double-Blind Method; D005682:Gadolinium / Q000008:administration & dosage; D019786:Gadolinium DTPA / Q000008:administration & dosage; D006801:Humans; D007089:Image Enhancement / Q000379:methods*; D007091:Image Processing, Computer-Assisted / Q000379:methods; D007223:Infant; D008279:Magnetic Resonance Imaging / Q000379:methods*; D008536:Meglumine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D009942:Organometallic Compounds / Q000008:administration & dosage; D011446:Prospective Studies; D012449:Safety; D013125:Spinal Neoplasms / Q000175:diagnosis*
chemical_list: D003287:Contrast Media; D009942:Organometallic Compounds; C064572:gadobenic acid; D008536:Meglumine; D005682:Gadolinium; D019786:Gadolinium DTPA